Despite considerable progress in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines worldwide, with poorer… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.
An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace current standard of care test in the UK according to a new study. In… read more.
The Ontario Institute for Cancer Research (OICR) continues to support Ontario drug discovery research by funding high-quality investigations of new therapies for some of the most prevalent pediatric… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.
Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer. Two studies focus on breastfeeding after breast cancer diagnosis and treatment. The studies found… read more.
NICE:(UK): Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti?CD20-based treatment. It is… read more.
As prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for medications. A new study finds that… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has approved Keytruda Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the… read more.
Giving higher doses per fraction of radiation therapy over a shorter time after breast cancer surgery significantly reduces the risk of side effects and improves quality of life… read more.
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved Balversa (erdafitinib) as a once-daily oral monotherapy for the treatment of adult… read more.
Just 28% of U.S. women are aware that a healthful diet can lower the risk of developing breast cancer, according to a just-released Physicians Committee for Responsible Medicine/Morning… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
